德国风湿病学会更新SARS-CoV-2大流行期间炎症性风湿病患者管理建议:方法学、关键信息与论证
德国风湿病学会(DGRh)在SARS-CoV-2大流行初期基于专家共识发布了第一版建议,随后基于截至2020年6月15日的文献检索(包括注册研究、横断面研究、病例报告和病例系列)制定了更新版建议,涉及预防措施(如卫生措施或疫苗接种)和免疫调节/免疫抑制药物的使用。本文报告关键推荐、制定建议的科学方法、管理附加思考,并在其他国际建议背景下讨论。
要点
- 更新版建议基于截至2020年6月15日的文献证据,涵盖预防措施和免疫调节/免疫抑制药物使用。
- 建议由德国风湿病学会制定,旨在为炎症性风湿病患者在COVID-19大流行期间提供管理指导。
- 本文提供关键推荐、方法学细节及与其他国际建议的对比讨论。
核心结论
- DGRh基于截至2020年6月15日的文献证据更新了炎症性风湿病患者在SARS-CoV-2/COVID-19大流行期间的管理建议。
研究设计与样本
- 德国风湿病学会(DGRh)基于截至2020年6月15日的文献检索制定更新版建议,文献类型包括注册研究、横断面研究、病例报告和病例系列。
主要发现
- 更新版建议涉及预防措施(如卫生措施或疫苗接种)和免疫调节/免疫抑制药物的使用。
临床怎么用
- 临床医生可参考该更新建议管理炎症性风湿病患者在COVID-19大流行期间的预防措施和免疫调节/免疫抑制药物使用。
局限性
- 第一版建议基于专家共识且 largely 非循证;更新版基于截至2020年6月15日的文献,证据可能有限。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
A few days after the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection was declared a pandemic, the German Society for Rheumatology (DGRh) compiled the first group of recommendations for the care of patients with inflammatory rheumatic diseases in light of SARS-CoV-2/coronavirus disease 2019 (COVID-19). These first recommendations were based on an expert consensus and were largely non-evidence-based. Now that the first scientific data from registries, cross-sectional studies, case reports and case series are available, the DGRh has developed a timely update. This update is based on a literature search of publications available through 15 June 2020 and addresses preventive measures (such as hygiene measures or vaccinations) and the use of immunomodulatory/immunosuppressive drugs. Driven by the commitment to let patients benefit from these new evidence-based recommendations as quickly as possible, the DGRh published the update in German on its homepage and in the Zeitschrift für Rheumatologie immediately after completion. Here we report the key recommendations to make them available to the international community, provide the scientific methodology used to develop the recommendations, give additional thoughts and advice for the management of patients with rheumatic diseases during the COVID-19 pandemic and discuss our recommendations in the context of other international recommendations.
引用
- Schulze-Koops H, Krüger K, Hoyer BF, et al. Updated recommendations of the German Society for Rheumatology for the care of patients with inflammatory rheumatic diseases in times of SARS-CoV-2-methodology, key messages and justifying information. Rheumatology (Oxford). 2021. PMID: 33502500. doi:10.1093/rheumatology/keab072
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。